| Liu, Ying Su |
NCT04468529: Evaluate the Effect of Injectable Neucardin on the Cardiac Function of Subjects With Chronic Systolic Heart Failure |
|
|
| Completed | 3 | 154 | RoW | Recombinant human Neuregulin for injection, Neucardin, Placebo | Zensun Sci. & Tech. Co., Ltd. | Chronic Systolic Heart Failure | 04/22 | 04/24 | | |
NCT05745259: Thrombolysis Treated With TNK-tPA in Acute Ischemic Stroke Patients （3T Stroke-Ⅲ） |
|
|
| Recruiting | 3 | 1630 | RoW | Alteplase, rt-PA, Tenecteplase, TNK-tPA | Beijing Tiantan Hospital, Jiangsu FENG HUA Biotech Pharmaceutical Co., Ltd, The Place Pharmaceutical(Jiangsu) Co., Ltd | Acute Ischemic Stroke | 11/23 | 03/24 | | |
| Recruiting | 3 | 918 | Europe, Canada, Japan, RoW | Zanidatamab, ZW25, JZP598, Tislelizumab, Trastuzumab, Herceptin®, Capecitabine, Oxaliplatin, Cisplatin, 5-Fluorouracil | Jazz Pharmaceuticals, BeiGene, Ltd. | Gastric Neoplasms, Gastroesophageal Adenocarcinoma, Esophageal Adenocarcinoma | 12/24 | 07/25 | | |
PANOVA-3, NCT03377491: Effect of Tumor Treating Fields (TTFields, 150 kHz) as Front-Line Treatment of Locally-advanced Pancreatic Adenocarcinoma Concomitant With Gemcitabine and Nab-paclitaxel |
|
|
| Completed | 3 | 571 | Europe, Canada, US, RoW | NovoTTF-200T, TTFields, Gemcitabine, nab paclitaxel | NovoCure Ltd. | Pancreas Adenocarcinoma | 10/24 | 10/24 | | |
JSKN003-302, NCT06079983: JSKN003 Versus Treatment Of Physician'S Choice For HER2-low, Unresectable and/or Metastatic Breast Cancer Subjects |
|
|
| Not yet recruiting | 3 | 400 | RoW | JSKN003, Capecitabine tablets, Gemcitabine hydrochloride for injection, Vinorelbine tartrate injection, Paclitaxel for injection (albumin-bound type), Docetaxel injection, Eribulin mesylate injection | Jiangsu Alphamab Biopharmaceuticals Co., Ltd | Breast Cancer | 04/25 | 03/29 | | |
STRIDES, NCT05490563: - a Clinical Research Study of an Investigational New Drug to Treat Spinocerebellar Ataxia |
|
|
| Terminated | 2/3 | 23 | Europe, US, RoW | SLS-005, Placebo | Seelos Therapeutics, Inc. | Spinocerebellar Ataxia Type 3 | 11/23 | 11/23 | | |
HNGC-004, NCT03939962: Camrelizumab Combined With FOLFOX Neoadjuvant Therapy for Resectable Gastric and Gastroesophageal Junctional Adenocarcinoma |
|
|
| Active, not recruiting | 2 | 60 | RoW | SHR1210 combined with FOLFOX | Henan Cancer Hospital | Gastric Cancer | 05/21 | 05/24 | | |
| Recruiting | 2 | 20 | RoW | camrelizumab, SHR-1210, Apatinib Mesylate | Henan Cancer Hospital | Advanced Gastric Carcinoma | 06/22 | 08/23 | | |
MRG002-002, NCT04837508: A Study of MRG002 in the Treatment of HER2-positive Unresectable, Locally Advanced or Metastatic Biliary Tract Cancer |
|
|
| Recruiting | 2 | 86 | RoW | MRG002 | Shanghai Miracogen Inc. | Advanced or Metastatic Biliary Tract Cancer | 12/22 | 08/23 | | |
NCT05188209: A Study to Evaluate the Efficacy and Safety of MRG003 in Patients With Advanced Gastric Cancer. |
|
|
| Recruiting | 2 | 60 | RoW | MRG003 | Shanghai Miracogen Inc. | Advanced or Metastatic Gastric Cancer, Advanced or Metastatic Gastroesophageal Junction Carcinoma | 03/23 | 08/23 | | |
| Not yet recruiting | 2 | 22 | RoW | Cadonilimab (®), a PD-1/CTLA-4 bi-specific antibody, Neoadjuvant therapy with Cadonilimab | LiuYing | Colorectal Cancer, Mismatch Repair-deficient (dMMR), Microsatellite Instability-high (MSI-H), Neoadjuvant Therapy | 12/23 | 12/23 | | |
NCT05247216: A Phase 2 Study of Hemay007 in Patients With Rheumatoid Arthritis |
|
|
| Completed | 2 | 140 | RoW | Hemay007 800 mg QD group, Hemay007 1200 mg QD group, Hemay007 600 mg QD group, Hemay007 placebo group | Tianjin Hemay Pharmaceutical Co., Ltd | Rheumatoid Arthritis | 06/23 | 06/23 | | |
NCT06173037: RC88 in Platinum-Resistant Recurrent Epithelial Ovarian Cancer, Fallopian Tube Cancer, and Primary Peritoneal Cancer |
|
|
| Recruiting | 2 | 88 | RoW | RC88, RC88 for Injection | RemeGen Co., Ltd. | Primary Peritoneal Cancer, Fallopian Tube Cancer, Epithelial Ovarian Cancer | 06/26 | 12/26 | | |
NCT06231680: Thalidomide Prevention or Treatment of Camrelizumab-induced Reactive Cutaneous Capillary Endothelial Proliferation (RCCEP) |
|
|
| Recruiting | 2 | 132 | RoW | Camrelizumab, SHR-1210, Thalidomide 50mg, Thalidomide, Thalidomide 100mg, Thalidomide 200mg, Chemotherapy, Platinum-based chemotherapy | Henan Cancer Hospital, First Affiliated Hospital Xi'an Jiaotong University | Lung Cancer, Nonsmall Cell, Esophageal Carcinoma | 06/24 | 09/25 | | |
NCT06227325: Disitamab Vedotin Combined With Sintilimab and XELOX Perioperative Treatment for Resectable Gastric Caner With HER2 Overexpression |
|
|
| Not yet recruiting | 2 | 27 | RoW | RC48 combined with Sintilimab and XELOX, Disitamab vedotin combined with Sintilimab and XELOX | Henan Cancer Hospital | Gastric Cancer | 12/24 | 12/25 | | |
NCT06293014: TAS-102 Combined With Bevacizumab for Second-line Maintenance Treatment of Advanced Colorectal Cancer |
|
|
| Recruiting | 2 | 224 | RoW | TAS-102+bevacizumab, Trifluridine and Tipiracil Hydrochloride Tablets; bevacizumab, Standard chemotherapy+bevacizumab, Bevacizumab | Henan Cancer Hospital | Colorectal Cancer | 10/25 | 11/26 | | |
NCT04774419: Radiation and TSR-042 (Dostarlimab) in People With Endometrial Cancer After They Receive Surgery |
|
|
| Recruiting | 2 | 62 | US | Intensity modulated radiation therapy (IMRT), Dostarlimab, TSR-042, Hypofractionated IMRT | Memorial Sloan Kettering Cancer Center, Tesaro, Inc. | Endometrial Cancer | 02/26 | 02/26 | | |
ACTIVATE, NCT05819359: Efficacy, Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of BIA 28-6156 in GBA-PD |
|
|
| Active, not recruiting | 2 | 237 | Europe, Canada, US | BIA 28-6156 10 mg, BIA 28-6156 60 mg, Placebo | Bial R&D Investments, S.A. | Parkinson's Disease | 03/26 | 07/26 | | |
NCT06166836: a Study to Evaluate the Safety and Efficacy of D-1553 Combined With IN10018 in KRAS G12C Mutant Solid Tumors |
|
|
| Recruiting | 1/2 | 140 | RoW | D1553, IN10018（Ifebemtinib）, BI 853520 | InxMed (Shanghai) Co., Ltd., InventisBio Co., Ltd | Solid Tumor | 12/25 | 12/26 | | |
NCT04755543: A Study of LP002 for the Treatment of Patients With Malignant Digestive System Neoplasms |
|
|
| Recruiting | 1 | 94 | RoW | LP002, Cisplatin, Fluorouracil, OH2 oncolytic virus | Taizhou HoudeAoke Biomedical Co., Ltd. | Digestive System Neoplasms | 06/21 | 06/22 | | |
| Enrolling by invitation | N/A | 200 | RoW | the paste group, the meridian group | The Affiliated Hospital of Qingdao University | Massage, Meridian, Pain | 05/21 | 05/21 | | |
| Recruiting | N/A | 10000 | RoW | Coronary angiography, CT angiography of aorta, CTA, CT angiography of pulmonary arteries., Electrocardiogram, ECG, Cardiac Troponin, Biomarkers of myocardial injury | West China Hospital | Chest Pain, Acute Aortic Dissection, Pulmonary Embolism, Acute Myocardial Infarction Type 1, Acute Coronary Syndrome | 10/21 | 10/22 | | |
NCT06087380: Auricular Acupressure on Improving Pain and Heart Variability in Patients After Cervical Spine Surgery |
|
|
| Completed | N/A | 62 | RoW | auricular acupressure, standard ward care | National Taipei University of Nursing and Health Sciences, Taipei Veterans General Hospital, Taiwan | Auricular Acupressure, Cervical Spine Surgery | 03/23 | 03/23 | | |
NCT05528484: Self-reported Outcomes of Patients in ERAS Nursing |
|
|
| Recruiting | N/A | 600 | RoW | ERAS nursing, non eras nursing | The Second Hospital of Shandong University | Enhanced Recovery After Surgery | 06/23 | 08/27 | | |
NCT05455099: A Multicenter Study of Ultrafast Pulse Wave Velocity in Obese Chinese Han Adults |
|
|
| Recruiting | N/A | 2400 | RoW | Carotid ultrasound examination 1, Carotid ultrasound examination 2 | First Hospital of China Medical University | Carotid Artery Diseases | 08/23 | 07/24 | | |
| Recruiting | N/A | 70 | US | | Koneksa Health, Merck Sharp & Dohme LLC, Regeneron Pharmaceuticals | Parkinson Disease | 08/25 | 09/25 | | |
MET-LVH, NCT05719337: Multi-Modality Echocardiographic Techniques in Pathological Left Ventricular Hypertrophy Adults |
|
|
| Recruiting | N/A | 660 | RoW | Echocardiography | First Hospital of China Medical University, Wuhan Union Hospital, China | Left Ventricular Hypertrophy | 08/24 | 08/25 | | |
| Gabra |
| Active, not recruiting | 3 | 9541 | Europe, Canada, Japan, US, RoW | Obicetrapib, Placebo | NewAmsterdam Pharma, Monash University | Atherosclerotic Cardiovascular Disease | 11/26 | 11/26 | | |
| Zheng |
| Active, not recruiting | 3 | 9541 | Europe, Canada, Japan, US, RoW | Obicetrapib, Placebo | NewAmsterdam Pharma, Monash University | Atherosclerotic Cardiovascular Disease | 11/26 | 11/26 | | |
JACKPOT8, NCT04105010: Assessing An Oral Janus Kinase Inhibitor, AZD4205 as Monotherapy in Patients Who Have PTCL |
|
|
| Completed | 2 | 171 | US, RoW | AZD4205 | Dizal Pharmaceuticals | Relapsed or Refractory Peripheral T Cell Lymphoma | 10/23 | 02/24 | | |
